![Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism - ScienceDirect Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S266637912100375X-fx1.jpg)
Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism - ScienceDirect
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
![Onco | Free Full-Text | Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review Onco | Free Full-Text | Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review](https://www.mdpi.com/onco/onco-01-00006/article_deploy/html/images/onco-01-00006-g001-550.jpg)
Onco | Free Full-Text | Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Ple
![Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/34/12/6991/F1.large.jpg)
Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research
![Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase–Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase - ScienceDirect Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase–Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002944016304072-gr2.jpg)
Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase–Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase - ScienceDirect
![Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/34/12/6991/F2.large.jpg)
Combination of Arginine Deprivation with TRAIL Treatment as a Targeted-Therapy for Mesothelioma | Anticancer Research
![A trial of a new drug called ADI-PEG 20 with chemotherapy for people with mesothelioma (ATOMIC-Meso) | Cancer Research UK A trial of a new drug called ADI-PEG 20 with chemotherapy for people with mesothelioma (ATOMIC-Meso) | Cancer Research UK](https://www.cancerresearchuk.org/sites/default/files/styles/cruk_wide_resp_breakpoint_one/public/14751_randomisation.png?itok=GbYffD24)
A trial of a new drug called ADI-PEG 20 with chemotherapy for people with mesothelioma (ATOMIC-Meso) | Cancer Research UK
![Frontiers | Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future Frontiers | Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future](https://www.frontiersin.org/files/Articles/497859/fonc-09-01519-HTML/image_m/fonc-09-01519-g001.jpg)
Frontiers | Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
![Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies | British Journal of Cancer Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-020-01230-8/MediaObjects/41416_2020_1230_Fig2_HTML.png)